コンテンツへスキップ
Merck

P134

(−)-Pentazocine

≥98% (HPLC)

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

実験式(ヒル表記法):
C19H27NO
CAS番号:
分子量:
285.42
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
206-634-6
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
protect from light
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

(−)-Pentazocine, ≥98% (HPLC)

InChI key

VOKSWYLNZZRQPF-CCKFTAQKSA-N

InChI

1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m1/s1

SMILES string

C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2C\C=C(\C)C

assay

≥98% (HPLC)

form

solid

Quality Level

drug control

USDEA Schedule IV; Home Office Schedule 3; stupéfiant (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet
kontrollierte Droge in Deutschland

storage condition

protect from light

color

white

solubility

DMSO: >10 mg/mL

originator

Sanofi Aventis

storage temp.

room temp

Biochem/physiol Actions

Pentazocine is an analgesic with both agonist and antagonist activities. It acts as a κ- and σ-opioid receptor agonist and partial mu-receptor antagonist. Pentazocine pre-treatment reduces the frequency of fentanyl-induced cough and improves the anesthetic effect.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

保管分類

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

P134-50MG:4548173205229 + P134-VAR: + P134-BULK: + P134-SMPL:

jan


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Ling-Wei Hsin et al.
Journal of medicinal chemistry, 53(3), 1392-1396 (2010-01-09)
A series of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines was synthesized. The (-)-enantiomers had much greater kappa-, mu-, and delta-opioid receptor binding affinity than the corresponding (+)-enantiomers. Compounds (-)-1a, (-)-1b, and (-)-1c displayed subnanomolar binding affinity for the mu-receptor, and (-)-1b had a
Daniele Zampieri et al.
Journal of medicinal chemistry, 52(17), 5380-5393 (2009-08-14)
Novel benzo[d]oxazol-2(3H)-one derivatives were designed and synthesized, and their affinities against sigma receptors were evaluated. On the basis of 31 compounds, a three-dimensional pharmacophore model for the sigma(1) receptor binding site was developed using the Catalyst 4.9 software package. The
Ralph Holl et al.
Journal of medicinal chemistry, 52(7), 2126-2137 (2009-02-27)
A series of 6,8-diazabicyclo[3.2.2]nonane derivatives bearing two aromatic moieties was prepared, the affinity toward sigma(1) and sigma(2) receptors was investigated, and the growth inhibition of six human tumor cell lines was determined. The enantiopure bicyclic ketones 5a ((+)-(1S,5S)-6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane-2,7,9-trione) and 5b
Carmen Abate et al.
Journal of medicinal chemistry, 54(4), 1022-1032 (2011-01-15)
1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high degree of lipophilicity, novel analogues of 1 with reduced lipophilic character were designed by substituting
Eva Grosse Maestrup et al.
Bioorganic & medicinal chemistry, 19(1), 393-405 (2010-12-04)
In order to develop a fluorinated radiotracer for imaging of σ(1) receptors in the central nervous system a series of (2-fluoroethyl) substituted spirocyclic piperidines 3 has been prepared. In the key step of the synthesis 2-bromocinnamaldehyde acetal 5 was added

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)